Funding for this research was provided by:
National Institutes of Health (P30 CA08748, R01 CA089208, R01 CA196648, R01 CA204999, P30 CA014599)
Susan G. Komen for the Cure (IR12223772)
Prostate Cancer Foundation (Movember Challenge Award)
The Cancer Research Foundation (Fletcher Scholar Award)
Shirley K. Koloseike Breast Cancer Research (Pilot Funding)
Text and Data Mining valid from 2019-07-24
Received: 24 January 2019
Accepted: 25 June 2019
First Online: 24 July 2019
Ethics approval and consent to participate
: All studies were carried out in accordance with and approval of the Institutional Animal Care and Use Committee of The University of Chicago and the Guide for the Care and Use of Laboratory Animals.
: Not applicable
: SDC is an inventor of methods patents concerning GR modulation in triple-negative breast cancer and prostate cancer that have been licensed to Corcept Therapeutics; while these patents do not involve ER+ breast cancer, they could be considered broadly relevant to this project. SCh has received research funds from Novartis and Daiichi Sankyo and ad hoc consulting honoraria from Novartis, Sermonix, Context Therapeutics, Eli Lilly, Sun Pharma, and Revolution Medicines, none of which appear directly relevant to this project. GFF receives support for an investigator-initiated Phase 1 trial in which Corcept Therapeutics provides GR modulator compound for treatment of a variety of cancer subtypes. The other authors declare that they have no competing interests.